businessbriefs
11:06in productionCh. 1 · State-Owned From Day One/ 11:06 · ceiling 15 min
Companies · Scandals

Sinopharm (company)

1998

A state-owned vaccine developer that delivered peer-reviewed efficacy — and sold 400,520 faulty doses.

Sinopharm is a Chinese state-owned enterprise founded on November 26, 1998. It developed the BBIBP-CorV inactivated virus COVID-19 vaccine, which showed 78.1% efficacy against symptomatic disease and 100% against severe disease in peer-reviewed Phase III trials. In 2009, it merged with China National Biotec Group. Its subsidiary Wuhan Institute of Biological Products was fined in November 2017 for selling 400,520 ineffective DPT vaccines.

CompaniesScandalsChinaVaccinesPhotographyChina across the network →
Chapters & takeaways4
  1. 1:06
    State-Owned From Day One

    Sinopharm is not a startup — it is a 1998 Chinese state-owned holding company built from four legacy pharmaceutical entities.

  2. 2:49
    The Biotec Merger

    The 2009 merger with China National Biotec Group gave Sinopharm direct vaccine R&D capacity — but also inherited its subsidiaries’ track record.

  3. 5:02
    What the Data Says

    BBIBP-CorV achieved 78.1% efficacy in peer-reviewed trials — but interim claims of 86% were never published in JAMA.

  4. 6:54
    The DPT Failure

    In November 2017, a Sinopharm subsidiary sold 400,520 ineffective DPT vaccines — then was fined.

Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • whatWorks
What does not
  • howItActuallyMakes
Study it if
  • public-health-policy-makers
  • regulatory-analysts
  • global-vaccine-distribution-researchers
Skip it if
  • investors-seeking-financial-transparency
  • entrepreneurs-looking-for-business-model-inspiration
The written brief1 min read

What the company or idea is

Sinopharm is a Chinese state-owned enterprise founded on November 26, 1998, as a holding company for four national pharmaceutical and medical device entities.

How it actually makes money

Sinopharm is a Chinese state-owned enterprise. It makes money through pharmaceutical manufacturing, distribution, and vaccine sales — but the material does not specify revenue streams, margins, pricing, or who pays (governments, insurers, individuals).

What works

BBIBP-CorV completed Phase III trials across seven countries with over 60,000 participants. Peer-reviewed JAMA results confirmed 78.1% efficacy against symptomatic disease and 100% against severe disease.

What does not

Sinopharm’s subsidiary sold 400,520 ineffective DPT vaccines in November 2017 and was fined. That failure reveals a gap between its public health mandate and quality control execution.

What to take from it

Sinopharm shows how state-backed biotech can rapidly scale vaccine development and deployment — while carrying legacy liabilities from pre-merger subsidiaries and inconsistent quality enforcement.

Is it worth your time

Yes — if you need to understand how state-owned vaccine developers operate under regulatory scrutiny, commercial pressure, and geopolitical demand. No — if you seek transparency on unit economics, profitability, or independent market validation.

Same desk · Companies4 of 217
12:57
MeituanWang Xing · 2010Meituan is a Chinese technology company headquartered in Beijing that operates a platform for local services, including on‑demand food delivery, in‑store services, consumer reviews under Dazhong Dianping, hotel and travel bookings, and instant retail. It monetises through fees on its platform, taking a commission on food delivery orders and charging merchants for booking and in‑store services. Meituan’s rapid user growth is driven by its extensive coverage of local services, its integration of food delivery, in‑store services, and hotel bookings creating a one‑stop shop, and its large merchant base of 14.5 million active merchants providing network effects. Meituan faces regulatory scrutiny in China, its 2021 post by Wang Xing triggered a 7.1 % share plunge and anti‑monopoly investigation, and the company has been subject to scrutiny by Beijing Municipal Human Resources and Social Security Bureau. Meituan demonstrates the power of a diversified local‑services platform, its ability to scale across cities and internationally shows the importance of network effects, and its regulatory challenges highlight the need for compliance awareness. Meituan offers a case study in rapid scaling and diversification, but its regulatory risks caution investors.
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
10:50
AbbVie2012AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.
11:08
Abu Dhabi National Oil Company1971ADNOC is the state-owned oil company of Abu Dhabi, UAE — founded by concession in 1939, ranked 12th globally by production, and expanding output to 5 million barrels per day by 2027. It is the UAE’s largest oil company. Output rose from ~2.5 mbpd in the 1990s to 2.9 mbpd in 2008 and 4.85 mbpd in 2024. It is described as efficient and well managed, but financially opaque. It is one of few oil companies increasing production amid climate pressure.
Up next in Business

SIX Swiss Exchange

1873 · 10:00

A national exchange built on merger, not markets — and still running the same core code that made it first in line.

Play nextBack to Companies
10:00